Home / Resource Library / Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Long term follow up of a study examining ibrutinib compared to chlorambucil for first line treatment of CLL.